NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

NASDAQ / LIVE COMPANY INTELLIGENCE

Aardvark Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERAARD
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / AARD COVERAGE

What’s moving Aardvark Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
GlobeNewswire

Portnoy Law Firm Announces Class Action on Behalf of Aardvark Therapeutics, Inc. Investors

The story matters when it changes Aardvark Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
The Conway Daily Sun

AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit

The story matters when it changes Aardvark Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
PR Newswire

Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Investors are testing whether Aardvark Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
GlobeNewswire

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

The story matters when it changes Aardvark Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
GlobeNewswire

AARD Shareholder Alert: Aardvark Therapeutics, Inc.

Investors are testing whether Aardvark Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
PR Newswire

Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit

The story matters when it changes Aardvark Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
07
mykxlg.com

Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

The story matters when it changes Aardvark Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
08
PR Newswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD

The development tests whether Aardvark Therapeutics, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
09
PR Newswire

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD

Investors are testing whether Aardvark Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
10
Morningstar

Kuehn Law Encourages Investors of Aardvark Therapeutics, Inc. to Contact Law Firm

The story matters when it changes Aardvark Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
11
ACCESS Newswire

Did You Lose Money on Aardvark Therapeutics, Inc. (AARD)? Levi & Korsinsky Urges Investors to Act Before October 13, 2026

The story matters when it changes Aardvark Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest AARD filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-11 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-03-23 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-08-17 · Period 2026-08-14SEC ↗8-KMaterial company eventFiled 2026-08-11 · Period 2026-08-11SEC ↗8-KMaterial company eventFiled 2026-06-12 · Period 2026-06-10SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-07-10 · Period 2026-08-14SEC ↗4Official SEC filingFiled 2026-09-11 · Period 2026-09-10SEC ↗
EARNINGS / QUARTERLY TRACKER

Aardvark Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.